AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35285810 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis
Number of subjects: 600
Study 35285859 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet adherence
Number of subjects: 2660
Study 35285859 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point higher DASH score (range, 7 to 35)
Number of subjects: 2660
Study 35285981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous stem cell transplantation
Number of subjects: 0
Study 35285981 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35286612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 595
Study 35286612 — intervention group
Group type: COMPARATOR
Intervention: Topical/traditional systemic agents
Number of subjects: 595
Study 35287034 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting buprenorphine subcutaneous injection
Number of subjects: 216
Study 35287119 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35287148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 59
Study 35287148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-wandering
Number of subjects: 59
Study 35287171 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 162
Study 35287171 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 162
Study 35287171 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 162
Study 35287469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 60 mg once daily administered orally
Number of subjects: 0
Study 35287613 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 260 mg/m²
Number of subjects: 261
Study 35287672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandoz biosimilar filgrastim (twice-daily)
Number of subjects: 245
Study 35287714 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation intervention
Number of subjects: 25
Study 35287714 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with Veterans and PC stakeholders
Number of subjects: 25
Study 35287714 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups with PC providers and staff
Number of subjects: 25
Study 35287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal ischemic lesions (no lesions, moderate lesions, severe lesions)
Number of subjects: 214
Study 35287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adrenaline dose during cardiopulmonary resuscitation
Number of subjects: 214
Study 35287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous proton pump inhibitor use
Number of subjects: 214
Study 35287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum bicarbonate on day 1
Number of subjects: 214
Study 35287719 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe lesions
Number of subjects: 214
Study 35287722 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMNC) infusion
Number of subjects: 19
Study 35287731 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with 85g of fresh lean beef
Number of subjects: 28
Study 35287731 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with 170g of fresh lean beef
Number of subjects: 28
Study 35287731 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined beef intake groups
Number of subjects: 28
Study 35287731 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 28
Study 35287760 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP)
Number of subjects: 18
Study 35287967 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg intravenously q4w and olaparib 300 mg 2dd until disease progression, unacceptable toxicity, or patient withdrawal
Number of subjects: 55
Study 35287967 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and olaparib
Number of subjects: 55
Study 35287972 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 89
Study 35287972 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 89
Study 35287972 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (overall)
Number of subjects: 89
Study 35288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal type
Number of subjects: 1302
Study 35288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma-like defects
Number of subjects: 1302
Study 35288144 — intervention group
Group type: EXPERIMENTAL
Intervention: High myopia-related defects
Number of subjects: 1302
Study 35288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined defects
Number of subjects: 1302
Study 35288144 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver and intraobserver agreement
Number of subjects: 1302
Study 35288462 — intervention group
Group type: EXPERIMENTAL
Intervention: ZEB1 expression in melanoma cells
Number of subjects: 60
Study 35288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib (100-400 mg once a day) plus epacadostat (50-300 mg two times per day)
Number of subjects: 142
Study 35288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib (100-400 mg once a day) plus parsaclisib (0.3-10 mg once a day)
Number of subjects: 142
Study 35288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib plus epacadostat
Number of subjects: 142
Study 35288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Itacitinib plus parsaclisib
Number of subjects: 142
Study 35288511 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-graded BSS scores
Number of subjects: 39
Study 35288511 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-graded daily average BSS scores
Number of subjects: 39
Study 35288511 — intervention group
Group type: EXPERIMENTAL
Intervention: AI stool characterization
Number of subjects: 39
Study 35289117 — intervention group
Group type: EXPERIMENTAL
Intervention: Public assistance group
Number of subjects: 3728
Study 35289117 — intervention group
Group type: COMPARATOR
Intervention: No public assistance group
Number of subjects: 3728
Study 35289267 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography-computerised tomography
Number of subjects: 380
Study 35289267 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced computerised tomography
Number of subjects: 380
Study 35289267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of maximum standardised uptake value and peak enhancement
Number of subjects: 380
Study 35289310 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid ELISA
Number of subjects: 0
Study 35289310 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibodies
Number of subjects: 0
Study 35289310 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 0
Study 35289316 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMO-Δex5
Number of subjects: 3
Study 35289316 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF stimulation of dermal fibroblasts
Number of subjects: 3
Study 35289329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 25
Study 35289396 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS programmes
Number of subjects: 747
Study 35289662 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic chest radiography (DCR)
Number of subjects: 0
Study 35289662 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 0
Study 35289694 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 47
Study 35289736 — intervention group
Group type: EXPERIMENTAL
Intervention: BET Protein Inhibition
Number of subjects: 0
Study 35289758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed educational and exercise-based mHealth intervention (BackFit app)
Number of subjects: 50
Study 35289758 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face educational and exercise-based intervention
Number of subjects: 50
Study 35289904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound identification of the RMM's inferior margin
Number of subjects: 100
Study 35289922 — intervention group
Group type: COMPARATOR
Intervention: Duct-to-mucosa pancreaticojejunostomy
Number of subjects: 1696
Study 35289922 — intervention group
Group type: COMPARATOR
Intervention: Modified Blumgart technique
Number of subjects: 1696
Study 35290073 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of fatigue trajectories
Number of subjects: 4173
Study 35290073 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of fatigue at diagnosis and year 1, 2, and 4 postdiagnosis
Number of subjects: 4173
Study 35290075 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncalcified plaque volume
Number of subjects: 196
Study 35290075 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification score
Number of subjects: 196
Study 35290075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcified plaque volume
Number of subjects: 196
Study 35290453 — intervention group
Group type: EXPERIMENTAL
Intervention: Concizumab 0.15 mg/kg (with potential dose escalation to 0.20 or 0.25 mg/kg)
Number of subjects: 61
Study 35290461 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based screening and treatment with artemether-lumefantrine
Number of subjects: 704
Study 35290467 — intervention group
Group type: EXPERIMENTAL
Intervention: P. falciparum CS2 parasites infection during the third trimester
Number of subjects: 0
Study 35290467 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent infections with P. falciparum CS2 parasites
Number of subjects: 0
Study 35290467 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple acute PM episodes and subsequent VAR2CSA immunization
Number of subjects: 0
Study 35290624 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster aspart
Number of subjects: 1091
Study 35290624 — intervention group
Group type: COMPARATOR
Intervention: IAsp
Number of subjects: 1091
Study 35291289 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-μg mRNA-1273 booster dose
Number of subjects: 0
Study 35291289 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (second dose of mRNA-1273)
Number of subjects: 0
Study 35291351 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 32
Study 35291821 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS conducted by paramedics
Number of subjects: 274
Study 35291821 — intervention group
Group type: COMPARATOR
Intervention: NIHSS-trained paramedics
Number of subjects: 274
Study 35291977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,250 mg orally once per day continuously plus capecitabine (1,000 mg/m2)
Number of subjects: 159
Study 35291977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine
Number of subjects: 159
Study 35291998 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe RSV infection
Number of subjects: 0
Study 35291998 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 35292028 — intervention group
Group type: EXPERIMENTAL
Intervention: ICHOM-SSS implementation in stroke unit care
Number of subjects: 24
Study 35292485 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise intervention (20-week duration, including supervised and unsupervised exercise sessions)
Number of subjects: 25
Study 35292485 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise intervention
Number of subjects: 25
Study 35292609 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 209
Study 35292609 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM
Number of subjects: 209
Study 35292609 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose adjustment based on TDM measurements
Number of subjects: 209
Study 35292609 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of European Committee on Antimicrobial Susceptibility Testing's epidemiological cutoff values
Number of subjects: 209
Study 35292700 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation at four GDF-15 related CpG sites (cg13033858, cg16936953, cg17150809, cg18608055)
Number of subjects: 19
Study 35292700 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint influences of cg16936953 and the score
Number of subjects: 19
Study 35292719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiology consultation
Number of subjects: 1269
Study 35292719 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 1269
Study 35292724 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg every 2 weeks)
Number of subjects: 15
Study 35292802 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched targeted therapies
Number of subjects: 787
Study 35292802 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA analysis
Number of subjects: 787
Study 35292905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback augmented mindfulness training (MT)
Number of subjects: 34
Study 35292924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-measured jugular venous pressure (U-JVP)
Number of subjects: 114
Study 35292924 — intervention group
Group type: COMPARATOR
Intervention: Direct central venous pressure (CVP) measurement
Number of subjects: 114
Study 35293148 — intervention group
Group type: EXPERIMENTAL
Intervention: ABTL0812
Number of subjects: 0
Study 35293148 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 0
Study 35293696 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear scintigraphy
Number of subjects: 0
Study 35293866 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIO (eHealth self-management intervention) combined with PMP (psychomotor physiotherapy)
Number of subjects: 5
Study 35293984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase (8 mg biweekly infusions) + oral MTX (15 mg/week) co-therapy
Number of subjects: 2
Study 35294044 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS)
Number of subjects: 1223856
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized allocation
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel interventional model
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Double blind masking
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Single center trials
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethical approval
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase IV trials
Number of subjects: 180
Study 35294135 — intervention group
Group type: EXPERIMENTAL
Intervention: Published trials
Number of subjects: 180
Study 35294335 — intervention group
Group type: EXPERIMENTAL
Intervention: FCV-19S modified for application during the perinatal period
Number of subjects: 178
Study 35294488 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology (AT) based on robotics and artificial intelligence
Number of subjects: 0
Study 35294522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + binimetinib (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off)
Number of subjects: 41
Study 35294522 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib + binimetinib
Number of subjects: 41
Study 35294527 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance (352 patients, 68.2%)
Number of subjects: 516
Study 35294527 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (120 patients, 23.3%)
Number of subjects: 516
Study 35294527 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatments (44 patients, 8.5%)
Number of subjects: 516
Study 35294527 — intervention group
Group type: EXPERIMENTAL
Intervention: CTNNB1 p.S45F mutation
Number of subjects: 516
Study 35294625 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 21300
Study 35294625 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 21300
Study 35294811 — intervention group
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy, single infusion of 6×10^13 vg/kg
Number of subjects: 134
Study 35294811 — intervention group
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) gene therapy
Number of subjects: 134
Study 35295414 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation (intrathecal therapy, spinal cord stimulation, or dorsal root ganglion stimulation)
Number of subjects: 2635
Study 35295414 — intervention group
Group type: COMPARATOR
Intervention: Pain medications
Number of subjects: 2635
Study 35295414 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2635
Study 35295414 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (medications)
Number of subjects: 2635
Study 35295458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigma-1 Receptor Changes
Number of subjects: 0
Study 35295488 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3 Treatment
Number of subjects: 0
Study 35295526 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Sleep Short Forms
Number of subjects: 0
Study 35295526 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35295591 — intervention group
Group type: COMPARATOR
Intervention: cBM-MSCs (bone marrow mesenchymal stem cells from cirrhosis patients)
Number of subjects: 10
Study 35295591 — intervention group
Group type: COMPARATOR
Intervention: cBM-MSCs
Number of subjects: 10
Study 35295614 — intervention group
Group type: EXPERIMENTAL
Intervention: Calligraphy activity
Number of subjects: 150
Study 35295614 — intervention group
Group type: COMPARATOR
Intervention: General activity
Number of subjects: 150
Study 35295665 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of intravenous amoxicillin (HDIVA)
Number of subjects: 112
Study 35295712 — intervention group
Group type: COMPARATOR
Intervention: High participation in nutrition-sensitive agriculture intervention
Number of subjects: 287
Study 35295712 — intervention group
Group type: COMPARATOR
Intervention: Medium participation in nutrition-sensitive agriculture intervention
Number of subjects: 287
Study 35295819 — intervention group
Group type: EXPERIMENTAL
Intervention: Regdanvimab 40 mg/kg
Number of subjects: 0
Study 35295819 — intervention group
Group type: EXPERIMENTAL
Intervention: Regdanvimab 80 mg/kg
Number of subjects: 0
Study 35295819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35296017 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 0
Study 35296017 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs (PDs)
Number of subjects: 191
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple medications
Number of subjects: 191
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications
Number of subjects: 191
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics, antidepressants, and sedative substances
Number of subjects: 191
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain medication
Number of subjects: 191
Study 35296254 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics and sedative substances
Number of subjects: 191
Study 35296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant sintilimab plus CapeOx (oxaliplatin and capecitabine)
Number of subjects: 0
Study 35296845 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35296895 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute Apgar score of 0
Number of subjects: 347
Study 35296895 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 10-minute Apgar score with other risk variables
Number of subjects: 347
Study 35296961 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmological treatment
Number of subjects: 82
Study 35296961 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 82
Study 35296961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopatherapy reduction
Number of subjects: 82
Study 35296961 — intervention group
Group type: COMPARATOR
Intervention: Visual complaints
Number of subjects: 82
Study 35296961 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolution of visual illusions and hallucinations
Number of subjects: 82
Study 35296975 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise (30 minutes at 60-80% of maximal heart rate)
Number of subjects: 40
Study 35296993 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab-dyyb (biosimilar to infliximab)
Number of subjects: 115
Study 35297025 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily
Number of subjects: 0
Study 35297025 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg once daily
Number of subjects: 0
Study 35297025 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg subcutaneous injection every 2 weeks
Number of subjects: 0
Study 35297025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35297944 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic surgical resection
Number of subjects: 2833
Study 35297944 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate lymph node dissection (≥1 N1 nodal station plus ≥3 N2 nodal stations)
Number of subjects: 2833
Study 35297944 — intervention group
Group type: EXPERIMENTAL
Intervention: Any adjuvant chemotherapy
Number of subjects: 2833
Study 35297944 — intervention group
Group type: EXPERIMENTAL
Intervention: At least 4 cycles of adjuvant platinum-based chemotherapy
Number of subjects: 2833
Study 35297944 — intervention group
Group type: EXPERIMENTAL
Intervention: Any cisplatin-based adjuvant chemotherapy
Number of subjects: 2833